{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T22:51:46Z","timestamp":1793400706656,"version":"4.5.0"},"reference-count":113,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T00:00:00Z","timestamp":1722816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T00:00:00Z","timestamp":1722816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"National Key Research and Development Program of China","award":["2021YFF1201300"],"award-info":[{"award-number":["2021YFF1201300"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-024-05537-5","type":"journal-article","created":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T13:04:01Z","timestamp":1722863041000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Genetic factors in the pathogenesis of cardio-oncology"],"prefix":"10.1186","volume":"22","author":[{"given":"Yalong","family":"Qi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhan","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hewei","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9432-1902","authenticated-orcid":false,"given":"Fei","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,5]]},"reference":[{"issue":"1","key":"5537_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7\u201330.","journal-title":"CA Cancer J Clin"},{"issue":"12","key":"5537_CR2","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","volume":"19","author":"JE Salem","year":"2018","unstructured":"Salem JE, Manouchehri A, Moey M, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol. 2018;19(12):1579\u201389.","journal-title":"Lancet Oncol"},{"issue":"2","key":"5537_CR3","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s11912-020-01002-w","volume":"23","author":"F Pirozzi","year":"2021","unstructured":"Pirozzi F, Poto R, Aran L, et al. Cardiovascular toxicity of Immune Checkpoint inhibitors: clinical risk factors. Curr Oncol Rep. 2021;23(2):13.","journal-title":"Curr Oncol Rep"},{"issue":"8","key":"5537_CR4","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1007\/s00018-019-03340-w","volume":"77","author":"K Leemasawat","year":"2020","unstructured":"Leemasawat K, Phrommintikul A, Chattipakorn SC, Chattipakorn N. Mechanisms and potential interventions associated with the cardiotoxicity of ErbB2-targeted drugs: insights from in vitro, in vivo, and clinical studies in breast cancer patients. Cell Mol Life Sci. 2020;77(8):1571\u201389.","journal-title":"Cell Mol Life Sci"},{"key":"5537_CR5","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.yjmcc.2022.03.010","volume":"167","author":"Y Kim","year":"2022","unstructured":"Kim Y, Seidman JG, Seidman CE. Genetics of cancer therapy-associated cardiotoxicity. J Mol Cell Cardiol. 2022;167:85\u201391.","journal-title":"J Mol Cell Cardiol"},{"issue":"41","key":"5537_CR6","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","volume":"43","author":"AR Lyon","year":"2022","unstructured":"Lyon AR, L\u00f3pez-Fern\u00e1ndez T, Couch LS, et al. 2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022;43(41):4229\u2013361.","journal-title":"Eur Heart J"},{"issue":"2","key":"5537_CR7","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.annonc.2019.10.023","volume":"31","author":"G Curigliano","year":"2020","unstructured":"Curigliano G, Lenihan D, Fradley M, et al. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Ann Oncol. 2020;31(2):171\u201390.","journal-title":"Ann Oncol"},{"key":"5537_CR8","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.semcancer.2019.08.006","volume":"60","author":"S Nobili","year":"2020","unstructured":"Nobili S, Lapucci A, Landini I, Coronnello M, Roviello G, Mini E. Role of ATP-binding cassette transporters in cancer initiation and progression. Semin Cancer Biol. 2020;60:72\u201395.","journal-title":"Semin Cancer Biol"},{"issue":"18","key":"5537_CR9","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.2217\/pgs-2021-0116","volume":"22","author":"P Sharma","year":"2021","unstructured":"Sharma P, Singh N, Sharma S. ATP binding cassette transporters and cancer: revisiting their controversial role. Pharmacogenomics. 2021;22(18):1211\u201335.","journal-title":"Pharmacogenomics"},{"issue":"1","key":"5537_CR10","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s12012-020-09595-1","volume":"21","author":"D Vaitiekus","year":"2021","unstructured":"Vaitiekus D, Muckiene G, Vaitiekiene A, et al. HFE Gene variants\u2019 impact on anthracycline-based Chemotherapy-Induced Subclinical Cardiotoxicity. Cardiovasc Toxicol. 2021;21(1):59\u201366.","journal-title":"Cardiovasc Toxicol"},{"key":"5537_CR11","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.freeradbiomed.2024.04.218","volume":"219","author":"W Shan","year":"2024","unstructured":"Shan W, Cui J, Song Y, et al. Itaconate as a key player in cardiovascular immunometabolism. Free Radic Biol Med. 2024;219:64\u201375.","journal-title":"Free Radic Biol Med"},{"issue":"17","key":"5537_CR12","doi-asserted-by":"publisher","first-page":"4051","DOI":"10.1002\/cncr.32948","volume":"126","author":"P Singh","year":"2020","unstructured":"Singh P, Wang X, Hageman L, et al. Association of GSTM1 null variant with anthracycline-related cardiomyopathy after childhood cancer-A children\u2019s Oncology Group ALTE03N1 report. Cancer. 2020;126(17):4051\u20138.","journal-title":"Cancer"},{"issue":"2","key":"5537_CR13","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1111\/cge.13968","volume":"100","author":"AM Berkman","year":"2021","unstructured":"Berkman AM, Hildebrandt MAT, Landstrom AP. The genetic underpinnings of anthracycline-induced cardiomyopathy predisposition. Clin Genet. 2021;100(2):132\u201343.","journal-title":"Clin Genet"},{"issue":"16","key":"5537_CR14","doi-asserted-by":"publisher","first-page":"887","DOI":"10.2217\/pgs-2022-0113","volume":"23","author":"C Udagawa","year":"2022","unstructured":"Udagawa C, Nakano MH, Yoshida T, et al. Association between genetic variants and the risk of nivolumab-induced immune-related adverse events. Pharmacogenomics. 2022;23(16):887\u2013901.","journal-title":"Pharmacogenomics"},{"issue":"2","key":"5537_CR15","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1111\/cge.14452","volume":"105","author":"MM Ni","year":"2024","unstructured":"Ni MM, Yang JF, Miao J, Xu J. Association between genetic variants of transmembrane transporters and susceptibility to anthracycline-induced cardiotoxicity: current understanding and existing evidence. Clin Genet. 2024;105(2):115\u201329.","journal-title":"Clin Genet"},{"issue":"2","key":"5537_CR16","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.trecan.2023.09.013","volume":"10","author":"L Duvivier","year":"2024","unstructured":"Duvivier L, Gerard L, Diaz A, Gillet JP. Linking ABC transporters to the hallmarks of cancer. Trends Cancer. 2024;10(2):124\u201334.","journal-title":"Trends Cancer"},{"key":"5537_CR17","doi-asserted-by":"crossref","unstructured":"Muckiene G, Vaitiekus D, Zaliaduonyte D et al. The impact of polymorphisms in ATP-Binding Cassette Transporter genes on Anthracycline-Induced Early Cardiotoxicity in patients with breast Cancer. J Cardiovasc Dev Dis. 2023;10(6).","DOI":"10.3390\/jcdd10060232"},{"issue":"1","key":"5537_CR18","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.jaccao.2023.11.008","volume":"6","author":"H Fonoudi","year":"2024","unstructured":"Fonoudi H, Jouni M, Cejas RB, et al. Functional validation of Doxorubicin-Induced cardiotoxicity-related genes. JACC CardioOncol. 2024;6(1):38\u201350.","journal-title":"JACC CardioOncol"},{"issue":"6","key":"5537_CR19","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1038\/tpj.2015.63","volume":"16","author":"M Krajinovic","year":"2016","unstructured":"Krajinovic M, Elbared J, Drouin S, et al. Polymorphisms of ABCC5 and NOS3 genes influence doxorubicin cardiotoxicity in survivors of childhood acute lymphoblastic leukemia. Pharmacogenomics J. 2016;16(6):530\u20135.","journal-title":"Pharmacogenomics J"},{"issue":"24","key":"5537_CR20","doi-asserted-by":"publisher","first-page":"3754","DOI":"10.1161\/CIRCULATIONAHA.105.576850","volume":"112","author":"L Wojnowski","year":"2005","unstructured":"Wojnowski L, Kulle B, Schirmer M, et al. NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. Circulation. 2005;112(24):3754\u201362.","journal-title":"Circulation"},{"issue":"3","key":"5537_CR21","doi-asserted-by":"publisher","first-page":"231","DOI":"10.2217\/pgs.15.162","volume":"17","author":"DL Hertz","year":"2016","unstructured":"Hertz DL, Caram MV, Kidwell KM, et al. Evidence for association of SNPs in ABCB1 and CBR3, but not RAC2, NCF4, SLC28A3 or TOP2B, with chronic cardiotoxicity in a cohort of breast cancer patients treated with anthracyclines. Pharmacogenomics. 2016;17(3):231\u201340.","journal-title":"Pharmacogenomics"},{"issue":"8","key":"5537_CR22","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1002\/pbc.24505","volume":"60","author":"H Visscher","year":"2013","unstructured":"Visscher H, Ross CJ, Rassekh SR, et al. Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline-induced cardiotoxicity in children. Pediatr Blood Cancer. 2013;60(8):1375\u201381.","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"5537_CR23","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1186\/s12885-022-10434-5","volume":"22","author":"EGE Hurkmans","year":"2022","unstructured":"Hurkmans EGE, Brand A, Verdonschot JAJ, Te Loo D, Coenen MJH. Pharmacogenetics of chemotherapy treatment response and -toxicities in patients with osteosarcoma: a systematic review. BMC Cancer. 2022;22(1):1326.","journal-title":"BMC Cancer"},{"issue":"10","key":"5537_CR24","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.2217\/pgs.15.61","volume":"16","author":"H Visscher","year":"2015","unstructured":"Visscher H, Rassekh SR, Sandor GS, et al. Genetic variants in SLC22A17 and SLC22A7 are associated with anthracycline-induced cardiotoxicity in children. Pharmacogenomics. 2015;16(10):1065\u201376.","journal-title":"Pharmacogenomics"},{"key":"5537_CR25","doi-asserted-by":"publisher","first-page":"600561","DOI":"10.3389\/fphar.2020.600561","volume":"11","author":"Y Yuan","year":"2020","unstructured":"Yuan Y, Fan S, Shu L, et al. Exploration the mechanism of Doxorubicin-Induced Heart failure in rats by Integration of Proteomics and Metabolomics Data. Front Pharmacol. 2020;11:600561.","journal-title":"Front Pharmacol"},{"key":"5537_CR26","doi-asserted-by":"crossref","unstructured":"Jensen BC, Parry TL, Huang W et al. Non-targeted metabolomics analysis of the effects of tyrosine kinase inhibitors Sunitinib and Erlotinib on Heart, muscle, liver and serum metabolism in vivo. Metabolites. 2017;7(3).","DOI":"10.3390\/metabo7030031"},{"issue":"13","key":"5537_CR27","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1200\/JCO.2010.34.3467","volume":"30","author":"H Visscher","year":"2012","unstructured":"Visscher H, Ross CJ, Rassekh SR, et al. Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children. J Clin Oncol. 2012;30(13):1422\u20138.","journal-title":"J Clin Oncol"},{"issue":"3","key":"5537_CR28","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1097\/FTD.0000000000001077","volume":"45","author":"A Siemens","year":"2023","unstructured":"Siemens A, Rassekh SR, Ross CJD, Carleton BC. Development of a dose-adjusted polygenic risk model for Anthracycline-Induced Cardiotoxicity. Ther Drug Monit. 2023;45(3):337\u201344.","journal-title":"Ther Drug Monit"},{"key":"5537_CR29","doi-asserted-by":"publisher","first-page":"102917","DOI":"10.1016\/j.redox.2023.102917","volume":"67","author":"MJ Ferreira","year":"2023","unstructured":"Ferreira MJ, Rodrigues TA, Pedrosa AG, et al. Glutathione and peroxisome redox homeostasis. Redox Biol. 2023;67:102917.","journal-title":"Redox Biol"},{"key":"5537_CR30","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.reprotox.2021.04.003","volume":"102","author":"UP Mohan","year":"2021","unstructured":"Mohan UP, Iqbal PBT, Arunachalam STA. Mechanisms of doxorubicin-mediated reproductive toxicity - A review. Reprod Toxicol. 2021;102:80\u20139.","journal-title":"Reprod Toxicol"},{"issue":"12","key":"5537_CR31","doi-asserted-by":"publisher","first-page":"2789","DOI":"10.1002\/cncr.23534","volume":"112","author":"JG Blanco","year":"2008","unstructured":"Blanco JG, Leisenring WM, Gonzalez-Covarrubias VM, et al. Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H:quinone oxidoreductase 1 gene NQO1 in patients who developed anthracycline-related congestive heart failure after childhood cancer. Cancer. 2008;112(12):2789\u201395.","journal-title":"Cancer"},{"issue":"13","key":"5537_CR32","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1200\/JCO.2011.34.8987","volume":"30","author":"JG Blanco","year":"2012","unstructured":"Blanco JG, Sun CL, Landier W, et al. Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes\u2013a report from the children\u2019s Oncology Group. J Clin Oncol. 2012;30(13):1415\u201321.","journal-title":"J Clin Oncol"},{"issue":"10","key":"5537_CR33","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1097\/FPC.0000000000000302","volume":"27","author":"DJ Serie","year":"2017","unstructured":"Serie DJ, Crook JE, Necela BM, et al. Genome-wide association study of cardiotoxicity in the NCCTG N9831 (Alliance) adjuvant trastuzumab trial. Pharmacogenet Genomics. 2017;27(10):378\u201385.","journal-title":"Pharmacogenet Genomics"},{"issue":"10","key":"5537_CR34","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1161\/CIRCRESAHA.118.313285","volume":"124","author":"A Petz","year":"2019","unstructured":"Petz A, Grandoch M, Gorski DJ, et al. Cardiac Hyaluronan synthesis is critically involved in the Cardiac Macrophage Response and promotes Healing after Ischemia Reperfusion Injury. Circ Res. 2019;124(10):1433\u201347.","journal-title":"Circ Res"},{"key":"5537_CR35","doi-asserted-by":"crossref","unstructured":"Berdiaki A, Neagu M, Spyridaki I, Kuskov A, Perez S, Nikitovic D. Hyaluronan and reactive oxygen Species Signaling-Novel cues from the Matrix? Antioxid (Basel). 2023;12(4).","DOI":"10.3390\/antiox12040824"},{"issue":"1","key":"5537_CR36","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1258\/ebm.2010.010206","volume":"236","author":"YZ Wang","year":"2011","unstructured":"Wang YZ, Cao ML, Liu YW, He YQ, Yang CX, Gao F. CD44 mediates oligosaccharides of hyaluronan-induced proliferation, tube formation and signal transduction in endothelial cells. Exp Biol Med (Maywood). 2011;236(1):84\u201390.","journal-title":"Exp Biol Med (Maywood)"},{"issue":"1","key":"5537_CR37","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1186\/s12951-024-02410-x","volume":"22","author":"SY Jeong","year":"2024","unstructured":"Jeong SY, Park BW, Kim J, et al. Hyaluronic acid stimulation of stem cells for cardiac repair: a cell-free strategy for myocardial infarct. J Nanobiotechnol. 2024;22(1):149.","journal-title":"J Nanobiotechnol"},{"issue":"7","key":"5537_CR38","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1200\/JCO.2013.50.3557","volume":"32","author":"X Wang","year":"2014","unstructured":"Wang X, Liu W, Sun CL, et al. Hyaluronan synthase 3 variant and anthracycline-related cardiomyopathy: a report from the children\u2019s oncology group. J Clin Oncol. 2014;32(7):647\u201353.","journal-title":"J Clin Oncol"},{"issue":"11","key":"5537_CR39","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1038\/nm.2919","volume":"18","author":"S Zhang","year":"2012","unstructured":"Zhang S, Liu X, Bawa-Khalfe T, et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med. 2012;18(11):1639\u201342.","journal-title":"Nat Med"},{"issue":"11","key":"5537_CR40","doi-asserted-by":"publisher","first-page":"e0276541","DOI":"10.1371\/journal.pone.0276541","volume":"17","author":"JS Hasbullah","year":"2022","unstructured":"Hasbullah JS, Scott EN, Bhavsar AP, et al. All-trans retinoic acid (ATRA) regulates key genes in the RARG-TOP2B pathway and reduces anthracycline-induced cardiotoxicity. PLoS ONE. 2022;17(11):e0276541.","journal-title":"PLoS ONE"},{"issue":"9","key":"5537_CR41","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1038\/ng.3374","volume":"47","author":"F Aminkeng","year":"2015","unstructured":"Aminkeng F, Bhavsar AP, Visscher H, et al. A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer. Nat Genet. 2015;47(9):1079\u201384.","journal-title":"Nat Genet"},{"issue":"12","key":"5537_CR42","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1016\/j.stem.2021.11.006","volume":"28","author":"DL Brooks","year":"2021","unstructured":"Brooks DL, Musunuru K. Detoxifying chemotherapy with genetics-guided stem cell modeling: a personalized affair. Cell Stem Cell. 2021;28(12):2039\u201340.","journal-title":"Cell Stem Cell"},{"issue":"12","key":"5537_CR43","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.1016\/j.stem.2021.08.006","volume":"28","author":"T Magdy","year":"2021","unstructured":"Magdy T, Jiang Z, Jouni M, et al. RARG variant predictive of doxorubicin-induced cardiotoxicity identifies a cardioprotective therapy. Cell Stem Cell. 2021;28(12):2076\u201389. e2077.","journal-title":"Cell Stem Cell"},{"issue":"6","key":"5537_CR44","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/s41569-023-00958-z","volume":"21","author":"M V\u00f6lkers","year":"2024","unstructured":"V\u00f6lkers M, Preiss T, Hentze MW. RNA-binding proteins in cardiovascular biology and disease: the beat goes on. Nat Rev Cardiol. 2024;21(6):361\u201378.","journal-title":"Nat Rev Cardiol"},{"issue":"1","key":"5537_CR45","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/0022-2836(91)90380-O","volume":"220","author":"S Brunak","year":"1991","unstructured":"Brunak S, Engelbrecht J, Knudsen S. Prediction of human mRNA donor and acceptor sites from the DNA sequence. J Mol Biol. 1991;220(1):49\u201365.","journal-title":"J Mol Biol"},{"issue":"8","key":"5537_CR46","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1200\/JCO.2015.63.4550","volume":"34","author":"X Wang","year":"2016","unstructured":"Wang X, Sun CL, Qui\u00f1ones-Lombra\u00f1a A, et al. CELF4 variant and anthracycline-related cardiomyopathy: a Children\u2019s Oncology Group Genome-Wide Association study. J Clin Oncol. 2016;34(8):863\u201370.","journal-title":"J Clin Oncol"},{"issue":"1","key":"5537_CR47","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1161\/CIRCULATIONAHA.118.037934","volume":"140","author":"P Garcia-Pavia","year":"2019","unstructured":"Garcia-Pavia P, Kim Y, Restrepo-Cordoba MA, et al. Genetic variants Associated with Cancer Therapy-Induced Cardiomyopathy. Circulation. 2019;140(1):31\u201341.","journal-title":"Circulation"},{"key":"5537_CR48","doi-asserted-by":"crossref","unstructured":"Hinson JT, Campbell SG. TTN truncation variants produce sarcomere-integrating proteins of uncertain functional significance. J Clin Invest. 2024;134(2).","DOI":"10.1172\/JCI175206"},{"issue":"7","key":"5537_CR49","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1056\/NEJMoa1110186","volume":"366","author":"DS Herman","year":"2012","unstructured":"Herman DS, Lam L, Taylor MR, et al. Truncations of titin causing dilated cardiomyopathy. N Engl J Med. 2012;366(7):619\u201328.","journal-title":"N Engl J Med"},{"issue":"1","key":"5537_CR50","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1161\/CIRCULATIONAHA.119.039573","volume":"140","author":"CM Haggerty","year":"2019","unstructured":"Haggerty CM, Damrauer SM, Levin MG, et al. Genomics-First evaluation of Heart Disease Associated with Titin-truncating variants. Circulation. 2019;140(1):42\u201354.","journal-title":"Circulation"},{"issue":"5","key":"5537_CR51","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1161\/CIRCULATIONAHA.119.037661","volume":"141","author":"F Mazzarotto","year":"2020","unstructured":"Mazzarotto F, Tayal U, Buchan RJ, et al. Reevaluating the genetic contribution of monogenic dilated cardiomyopathy. Circulation. 2020;141(5):387\u201398.","journal-title":"Circulation"},{"key":"5537_CR52","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1146\/annurev-genom-083118-015306","volume":"20","author":"R Yotti","year":"2019","unstructured":"Yotti R, Seidman CE, Seidman JG. Advances in the genetic basis and Pathogenesis of Sarcomere Cardiomyopathies. Annu Rev Genomics Hum Genet. 2019;20:129\u201353.","journal-title":"Annu Rev Genomics Hum Genet"},{"issue":"20","key":"5537_CR53","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1016\/j.jacc.2018.03.462","volume":"71","author":"JS Ware","year":"2018","unstructured":"Ware JS, Amor-Salamanca A, Tayal U, et al. Genetic etiology for Alcohol-Induced Cardiac Toxicity. J Am Coll Cardiol. 2018;71(20):2293\u2013302.","journal-title":"J Am Coll Cardiol"},{"issue":"19","key":"5537_CR54","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1161\/CIRCULATIONAHA.120.052395","volume":"143","author":"R Goli","year":"2021","unstructured":"Goli R, Li J, Brandimarto J, et al. Genetic and phenotypic Landscape of Peripartum Cardiomyopathy. Circulation. 2021;143(19):1852\u201362.","journal-title":"Circulation"},{"issue":"1","key":"5537_CR55","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.ejcsup.2014.03.002","volume":"12","author":"BM Aleman","year":"2014","unstructured":"Aleman BM, Moser EC, Nuver J, et al. Cardiovascular disease after cancer therapy. EJC Suppl. 2014;12(1):18\u201328.","journal-title":"EJC Suppl"},{"issue":"8","key":"5537_CR56","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1161\/CIRCULATIONAHA.107.690487","volume":"116","author":"K Lemmens","year":"2007","unstructured":"Lemmens K, Doggen K, De Keulenaer GW. Role of neuregulin-1\/ErbB signaling in cardiovascular physiology and disease: implications for therapy of heart failure. Circulation. 2007;116(8):954\u201360.","journal-title":"Circulation"},{"issue":"1","key":"5537_CR57","first-page":"22","volume":"9","author":"H Eaton","year":"2023","unstructured":"Eaton H, Timm KN. Mechanisms of trastuzumab induced cardiotoxicity - is exercise a potential treatment? Cardiooncology. 2023;9(1):22.","journal-title":"Cardiooncology"},{"key":"5537_CR58","doi-asserted-by":"publisher","first-page":"119760","DOI":"10.1016\/j.lfs.2021.119760","volume":"280","author":"M Anjos","year":"2021","unstructured":"Anjos M, Fontes-Oliveira M, Costa VM, Santos M, Ferreira R. An update of the molecular mechanisms underlying doxorubicin plus trastuzumab induced cardiotoxicity. Life Sci. 2021;280:119760.","journal-title":"Life Sci"},{"issue":"10075","key":"5537_CR59","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/S0140-6736(16)32616-2","volume":"389","author":"D Cameron","year":"2017","unstructured":"Cameron D, Piccart-Gebhart MJ, Gelber RD, et al. 11 years\u2019 follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin adjuvant (HERA) trial. Lancet. 2017;389(10075):1195\u2013205.","journal-title":"Lancet"},{"issue":"13","key":"5537_CR60","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1016\/j.ejca.2015.05.028","volume":"51","author":"X Pivot","year":"2015","unstructured":"Pivot X, Suter T, Nabholtz JM, et al. Cardiac toxicity events in the PHARE trial, an adjuvant trastuzumab randomised phase III study. Eur J Cancer. 2015;51(13):1660\u20136.","journal-title":"Eur J Cancer"},{"issue":"4","key":"5537_CR61","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S1470-2045(19)30863-0","volume":"21","author":"SM Swain","year":"2020","unstructured":"Swain SM, Miles D, Kim SB, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol. 2020;21(4):519\u201330.","journal-title":"Lancet Oncol"},{"issue":"3","key":"5537_CR62","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1093\/carcin\/bgh342","volume":"26","author":"B Frank","year":"2005","unstructured":"Frank B, Hemminki K, Wirtenberger M, et al. The rare ERBB2 variant Ile654Val is associated with an increased familial breast cancer risk. Carcinogenesis. 2005;26(3):643\u20137.","journal-title":"Carcinogenesis"},{"issue":"6","key":"5537_CR63","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1093\/annonc\/mdu111","volume":"25","author":"X Han","year":"2014","unstructured":"Han X, Diao L, Xu Y, et al. Association between the HER2 Ile655Val polymorphism and response to trastuzumab in women with operable primary breast cancer. Ann Oncol. 2014;25(6):1158\u201364.","journal-title":"Ann Oncol"},{"issue":"5","key":"5537_CR64","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1093\/jnci\/92.5.412","volume":"92","author":"D Xie","year":"2000","unstructured":"Xie D, Shu XO, Deng Z, et al. Population-based, case-control study of HER2 genetic polymorphism and breast cancer risk. J Natl Cancer Inst. 2000;92(5):412\u20137.","journal-title":"J Natl Cancer Inst"},{"issue":"8","key":"5537_CR65","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1093\/annonc\/mdm181","volume":"18","author":"S Beauclair","year":"2007","unstructured":"Beauclair S, Formento P, Fischel JL, et al. Role of the HER2 [Ile655Val] genetic polymorphism in tumorogenesis and in the risk of trastuzumab-related cardiotoxicity. Ann Oncol. 2007;18(8):1335\u201341.","journal-title":"Ann Oncol"},{"key":"5537_CR66","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1186\/s12885-015-1298-6","volume":"15","author":"SE Stanton","year":"2015","unstructured":"Stanton SE, Ward MM, Christos P, et al. Pro1170 ala polymorphism in HER2-neu is associated with risk of trastuzumab cardiotoxicity. BMC Cancer. 2015;15:267.","journal-title":"BMC Cancer"},{"issue":"8","key":"5537_CR67","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1001\/jamaoncol.2016.1726","volume":"2","author":"AH Boekhout","year":"2016","unstructured":"Boekhout AH, Gietema JA, Milojkovic Kerklaan B, et al. Angiotensin II-Receptor inhibition with Candesartan to Prevent Trastuzumab-Related Cardiotoxic effects in patients with early breast Cancer: a Randomized Clinical Trial. JAMA Oncol. 2016;2(8):1030\u20137.","journal-title":"JAMA Oncol"},{"issue":"12","key":"5537_CR68","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1248\/bpb.b19-00527","volume":"42","author":"MH Nakano","year":"2019","unstructured":"Nakano MH, Udagawa C, Shimo A, et al. A Genome-Wide Association Study Identifies Five Novel Genetic Markers for Trastuzumab-Induced Cardiotoxicity in Japanese Population. Biol Pharm Bull. 2019;42(12):2045\u201353.","journal-title":"Biol Pharm Bull"},{"issue":"2","key":"5537_CR69","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1111\/cas.13471","volume":"109","author":"C Udagawa","year":"2018","unstructured":"Udagawa C, Nakamura H, Ohnishi H, et al. Whole exome sequencing to identify genetic markers for trastuzumab-induced cardiotoxicity. Cancer Sci. 2018;109(2):446\u201352.","journal-title":"Cancer Sci"},{"key":"5537_CR70","doi-asserted-by":"crossref","unstructured":"Cort\u00e9s J, Hurvitz SA, Im SA et al. Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial. Nat Med. 2024.","DOI":"10.1038\/s41591-024-03021-7"},{"issue":"5","key":"5537_CR71","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/S1470-2045(24)00128-1","volume":"25","author":"T Fehm","year":"2024","unstructured":"Fehm T, Cottone F, Dunton K, et al. Trastuzumab Deruxtecan versus treatment of physician\u2019s choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): patient-reported outcomes from a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2024;25(5):614\u201325.","journal-title":"Lancet Oncol"},{"key":"5537_CR72","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1146\/annurev-pharmtox-022820-093805","volume":"61","author":"A Geraud","year":"2021","unstructured":"Geraud A, Gougis P, Vozy A, et al. Clinical pharmacology and interplay of Immune Checkpoint agents: a Yin-Yang Balance. Annu Rev Pharmacol Toxicol. 2021;61:85\u2013112.","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"18","key":"5537_CR73","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","volume":"375","author":"DB Johnson","year":"2016","unstructured":"Johnson DB, Balko JM, Compton ML, et al. Fulminant myocarditis with combination Immune Checkpoint Blockade. N Engl J Med. 2016;375(18):1749\u201355.","journal-title":"N Engl J Med"},{"issue":"10124","key":"5537_CR74","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/S0140-6736(18)30533-6","volume":"391","author":"JJ Moslehi","year":"2018","unstructured":"Moslehi JJ, Salem JE, Sosman JA, Lebrun-Vignes B, Johnson DB. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet. 2018;391(10124):933.","journal-title":"Lancet"},{"issue":"1","key":"5537_CR75","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.jaccao.2021.01.004","volume":"3","author":"S Waliany","year":"2021","unstructured":"Waliany S, Neal JW, Reddy S, et al. Myocarditis Surveillance with High-Sensitivity Troponin I during Cancer Treatment with Immune Checkpoint inhibitors. JACC CardioOncol. 2021;3(1):137\u20139.","journal-title":"JACC CardioOncol"},{"issue":"2","key":"5537_CR76","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1161\/CIRCULATIONAHA.118.034497","volume":"140","author":"MP Bonaca","year":"2019","unstructured":"Bonaca MP, Olenchock BA, Salem JE, et al. Myocarditis in the setting of Cancer therapeutics: proposed case definitions for emerging clinical syndromes in Cardio-Oncology. Circulation. 2019;140(2):80\u201391.","journal-title":"Circulation"},{"key":"5537_CR77","doi-asserted-by":"publisher","first-page":"102536","DOI":"10.1016\/j.eclinm.2024.102536","volume":"70","author":"P Gougis","year":"2024","unstructured":"Gougis P, Jochum F, Abbar B, et al. Clinical spectrum and evolution of immune-checkpoint inhibitors toxicities over a decade-a worldwide perspective. EClinicalMedicine. 2024;70:102536.","journal-title":"EClinicalMedicine"},{"issue":"12","key":"5537_CR78","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","volume":"4","author":"DY Wang","year":"2018","unstructured":"Wang DY, Salem JE, Cohen JV, et al. Fatal toxic effects Associated with Immune Checkpoint inhibitors: a systematic review and Meta-analysis. JAMA Oncol. 2018;4(12):1721\u20138.","journal-title":"JAMA Oncol"},{"issue":"6","key":"5537_CR79","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/s41569-019-0164-7","volume":"16","author":"KH Simons","year":"2019","unstructured":"Simons KH, de Jong A, Jukema JW, de Vries MR, Arens R, Quax PHA. T cell co-stimulation and co-inhibition in cardiovascular disease: a double-edged sword. Nat Rev Cardiol. 2019;16(6):325\u201343.","journal-title":"Nat Rev Cardiol"},{"issue":"31","key":"5537_CR80","doi-asserted-by":"publisher","first-page":"2938","DOI":"10.1093\/eurheartj\/ehaa484","volume":"41","author":"A Shami","year":"2020","unstructured":"Shami A, Atzler D, Bosmans LA, et al. Glucocorticoid-induced tumour necrosis factor receptor family-related protein (GITR) drives atherosclerosis in mice and is associated with an unstable plaque phenotype and cerebrovascular events in humans. Eur Heart J. 2020;41(31):2938\u201348.","journal-title":"Eur Heart J"},{"issue":"2","key":"5537_CR81","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1161\/CIRCRESAHA.119.316062","volume":"129","author":"C Kassiteridi","year":"2021","unstructured":"Kassiteridi C, Cole JE, Griseri T, et al. CD200 limits Monopoiesis and Monocyte Recruitment in Atherosclerosis. Circ Res. 2021;129(2):280\u201395.","journal-title":"Circ Res"},{"issue":"1","key":"5537_CR82","doi-asserted-by":"publisher","first-page":"3754","DOI":"10.1038\/s41467-021-23909-z","volume":"12","author":"M Lacy","year":"2021","unstructured":"Lacy M, B\u00fcrger C, Shami A, et al. Cell-specific and divergent roles of the CD40L-CD40 axis in atherosclerotic vascular disease. Nat Commun. 2021;12(1):3754.","journal-title":"Nat Commun"},{"issue":"48","key":"5537_CR83","doi-asserted-by":"publisher","first-page":"3937","DOI":"10.1093\/eurheartj\/ehz283","volume":"40","author":"E Lutgens","year":"2019","unstructured":"Lutgens E, Atzler D, D\u00f6ring Y, Duchene J, Steffens S, Weber C. Immunotherapy for cardiovascular disease. Eur Heart J. 2019;40(48):3937\u201346.","journal-title":"Eur Heart J"},{"issue":"6","key":"5537_CR84","doi-asserted-by":"publisher","first-page":"111611","DOI":"10.1016\/j.celrep.2022.111611","volume":"41","author":"T Won","year":"2022","unstructured":"Won T, Kalinoski HM, Wood MK, et al. Cardiac myosin-specific autoimmune T cells contribute to immune-checkpoint-inhibitor-associated myocarditis. Cell Rep. 2022;41(6):111611.","journal-title":"Cell Rep"},{"key":"5537_CR85","doi-asserted-by":"publisher","first-page":"e075859","DOI":"10.1136\/bmj-2023-075859","volume":"385","author":"NL Palaskas","year":"2024","unstructured":"Palaskas NL, Ali HJ, Koutroumpakis E, Ganatra S, Deswal A. Cardiovascular toxicity of immune therapies for cancer. BMJ. 2024;385:e075859.","journal-title":"BMJ"},{"issue":"12","key":"5537_CR86","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1038\/nm955","volume":"9","author":"T Okazaki","year":"2003","unstructured":"Okazaki T, Tanaka Y, Nishio R, et al. Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice. Nat Med. 2003;9(12):1477\u201383.","journal-title":"Nat Med"},{"issue":"7937","key":"5537_CR87","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1038\/s41586-022-05432-3","volume":"611","author":"ML Axelrod","year":"2022","unstructured":"Axelrod ML, Meijers WC, Screever EM, et al. T cells specific for \u03b1-myosin drive immunotherapy-related myocarditis. Nature. 2022;611(7937):818\u201326.","journal-title":"Nature"},{"issue":"4","key":"5537_CR88","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1093\/eurheartj\/ehab430","volume":"43","author":"L Michel","year":"2022","unstructured":"Michel L, Helfrich I, Hendgen-Cotta UB, et al. Targeting early stages of cardiotoxicity from anti-PD1 immune checkpoint inhibitor therapy. Eur Heart J. 2022;43(4):316\u201329.","journal-title":"Eur Heart J"},{"issue":"7","key":"5537_CR89","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/s41419-020-02778-2","volume":"11","author":"W Xia","year":"2020","unstructured":"Xia W, Zou C, Chen H, Xie C, Hou M. Immune checkpoint inhibitor induces cardiac injury through polarizing macrophages via modulating microRNA-34a\/Kruppel-like factor 4 signaling. Cell Death Dis. 2020;11(7):575.","journal-title":"Cell Death Dis"},{"issue":"5502","key":"5537_CR90","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1126\/science.291.5502.319","volume":"291","author":"H Nishimura","year":"2001","unstructured":"Nishimura H, Okazaki T, Tanaka Y, et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science. 2001;291(5502):319\u201322.","journal-title":"Science"},{"issue":"25","key":"5537_CR91","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1161\/CIRCULATIONAHA.119.041694","volume":"140","author":"E Martini","year":"2019","unstructured":"Martini E, Kunderfranco P, Peano C, et al. Single-cell sequencing of Mouse Heart Immune infiltrate in pressure overload-driven heart failure reveals extent of Immune activation. Circulation. 2019;140(25):2089\u2013107.","journal-title":"Circulation"},{"issue":"6","key":"5537_CR92","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1038\/ejhg.2010.3","volume":"18","author":"V Ruppert","year":"2010","unstructured":"Ruppert V, Meyer T, Struwe C, et al. Evidence for CTLA4 as a susceptibility gene for dilated cardiomyopathy. Eur J Hum Genet. 2010;18(6):694\u20139.","journal-title":"Eur J Hum Genet"},{"issue":"3","key":"5537_CR93","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1161\/CIRCRESAHA.106.147124","volume":"101","author":"VA Love","year":"2007","unstructured":"Love VA, Grabie N, Duramad P, Stavrakis G, Sharpe A, Lichtman A. CTLA-4 ablation and interleukin-12 driven differentiation synergistically augment cardiac pathogenicity of cytotoxic T lymphocytes. Circ Res. 2007;101(3):248\u201357.","journal-title":"Circ Res"},{"issue":"3","key":"5537_CR94","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1161\/HYPERTENSIONAHA.116.07579","volume":"68","author":"H Wang","year":"2016","unstructured":"Wang H, Kwak D, Fassett J, et al. CD28\/B7 Deficiency attenuates Systolic Overload-Induced Congestive Heart failure, myocardial and pulmonary inflammation, and activated T cell Accumulation in the heart and lungs. Hypertension. 2016;68(3):688\u201396.","journal-title":"Hypertension"},{"issue":"5","key":"5537_CR95","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1007\/s12265-022-10240-1","volume":"15","author":"Y Xu","year":"2022","unstructured":"Xu Y, Chen R, Yan J, Zang G, Shao C, Wang Z. CD137 Signal mediates Cardiac Ischemia-Reperfusion Injury by regulating the necrosis of Cardiomyocytes. J Cardiovasc Transl Res. 2022;15(5):1163\u201375.","journal-title":"J Cardiovasc Transl Res"},{"key":"5537_CR96","doi-asserted-by":"publisher","first-page":"14680","DOI":"10.1038\/ncomms14680","volume":"8","author":"M Kallikourdis","year":"2017","unstructured":"Kallikourdis M, Martini E, Carullo P, et al. T cell costimulation blockade blunts pressure overload-induced heart failure. Nat Commun. 2017;8:14680.","journal-title":"Nat Commun"},{"key":"5537_CR97","doi-asserted-by":"publisher","first-page":"759972","DOI":"10.3389\/fcvm.2021.759972","volume":"8","author":"E Kushnareva","year":"2021","unstructured":"Kushnareva E, Kushnarev V, Artemyeva A, Mitrofanova L, Moiseeva O. Myocardial PD-L1 expression in patients with ischemic and non-ischemic heart failure. Front Cardiovasc Med. 2021;8:759972.","journal-title":"Front Cardiovasc Med"},{"issue":"4","key":"5537_CR98","doi-asserted-by":"publisher","first-page":"2330","DOI":"10.1002\/ehf2.14304","volume":"10","author":"EM Screever","year":"2023","unstructured":"Screever EM, Yousif LIE, Moslehi JJ, et al. Circulating immune checkpoints predict heart failure outcomes. ESC Heart Fail. 2023;10(4):2330\u20137.","journal-title":"ESC Heart Fail"},{"issue":"2","key":"5537_CR99","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1111\/imm.13770","volume":"172","author":"B Lou","year":"2024","unstructured":"Lou B, Guo M, Zheng T, et al. Single-cell RNA sequencing reveals the altered innate immunity in immune checkpoint inhibitor-related myocarditis. Immunology. 2024;172(2):235\u201351.","journal-title":"Immunology"},{"issue":"4","key":"5537_CR100","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.21873\/anticanres.14175","volume":"40","author":"L Simeti\u0107","year":"2020","unstructured":"Simeti\u0107 L, Bla\u017ei\u010devi\u0107 K, Me\u0111ugorac K, Gol\u010di\u0107 M, Herceg D. Relative change in S100 as a biomarker of survival in patients with metastatic melanoma treated with Pembrolizumab. Anticancer Res. 2020;40(4):2157\u201363.","journal-title":"Anticancer Res"},{"issue":"5","key":"5537_CR101","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1038\/s41418-023-01126-z","volume":"30","author":"RRJ Low","year":"2023","unstructured":"Low RRJ, Fung KY, Gao H, et al. S100 family proteins are linked to organoid morphology and EMT in pancreatic cancer. Cell Death Differ. 2023;30(5):1155\u201365.","journal-title":"Cell Death Differ"},{"key":"5537_CR102","doi-asserted-by":"crossref","unstructured":"Li M, Cui P, Dai W et al. S100 protein family: emerging role and mechanism in digestive tract cancer (review). Int J Oncol. 2024;64(6).","DOI":"10.3892\/ijo.2024.5647"},{"key":"5537_CR103","doi-asserted-by":"publisher","first-page":"110156","DOI":"10.1016\/j.biopha.2020.110156","volume":"127","author":"X Hua","year":"2020","unstructured":"Hua X, Zhang H, Jia J, Chen S, Sun Y, Zhu X. Roles of S100 family members in drug resistance in tumors: Status and prospects. Biomed Pharmacother. 2020;127:110156.","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"5537_CR104","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1038\/s41467-018-03961-y","volume":"9","author":"H Zemmour","year":"2018","unstructured":"Zemmour H, Planer D, Magenheim J, et al. Non-invasive detection of human cardiomyocyte death using methylation patterns of circulating DNA. Nat Commun. 2018;9(1):1443.","journal-title":"Nat Commun"},{"issue":"7943","key":"5537_CR105","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/s41586-022-05580-6","volume":"613","author":"N Loyfer","year":"2023","unstructured":"Loyfer N, Magenheim J, Peretz A, et al. A DNA methylation atlas of normal human cell types. Nature. 2023;613(7943):355\u201364.","journal-title":"Nature"},{"issue":"1","key":"5537_CR106","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s12967-022-03234-9","volume":"20","author":"J Ren","year":"2022","unstructured":"Ren J, Jiang L, Liu X, et al. Heart-specific DNA methylation analysis in plasma for the investigation of myocardial damage. J Transl Med. 2022;20(1):36.","journal-title":"J Transl Med"},{"key":"5537_CR107","doi-asserted-by":"crossref","unstructured":"Zhang F, Zhang L, Hu G et al. Rectifying METTL4-Mediated N(6)-Methyladenine excess in mitochondrial DNA alleviates Heart failure. Circulation. 2024.","DOI":"10.1161\/CIRCULATIONAHA.123.068358"},{"key":"5537_CR108","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3390\/cancers13246291","volume":"13","author":"MA Bauer","year":"2021","unstructured":"Bauer MA, Todorova VK, Stone A, et al. Genome-wide DNA methylation signatures predict the Early Asymptomatic Doxorubicin-Induced cardiotoxicity in breast Cancer. Cancers (Basel). 2021;13:24.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"5537_CR109","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jaccao.2022.12.007","volume":"5","author":"R Velusamy","year":"2023","unstructured":"Velusamy R, Nolan M, Murphy A, Thavendiranathan P, Marwick TH. Screening for coronary artery disease in Cancer survivors: JACC: CardioOncology State-of-the-art review. JACC CardioOncol. 2023;5(1):22\u201338.","journal-title":"JACC CardioOncol"},{"issue":"1","key":"5537_CR110","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s13058-021-01465-0","volume":"23","author":"L Liou","year":"2021","unstructured":"Liou L, Kaptoge S, Dennis J, et al. Genomic risk prediction of coronary artery disease in women with breast cancer: a prospective cohort study. Breast Cancer Res. 2021;23(1):94.","journal-title":"Breast Cancer Res"},{"issue":"8","key":"5537_CR111","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1038\/s41591-022-01902-3","volume":"28","author":"Y Sapkota","year":"2022","unstructured":"Sapkota Y, Qiu W, Dixon SB, et al. Genetic risk score enhances the risk prediction of severe obesity in adult survivors of childhood cancer. Nat Med. 2022;28(8):1590\u20138.","journal-title":"Nat Med"},{"issue":"3","key":"5537_CR112","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1161\/CIR.0000000000001158","volume":"148","author":"D Addison","year":"2023","unstructured":"Addison D, Branch M, Baik AH, et al. Equity in Cardio-Oncology Care and Research: A Scientific Statement from the American Heart Association. Circulation. 2023;148(3):297\u2013308.","journal-title":"Circulation"},{"issue":"2","key":"5537_CR113","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.jaccao.2021.05.001","volume":"3","author":"M Fazal","year":"2021","unstructured":"Fazal M, Malisa J, Rhee JW, Witteles RM, Rodriguez F. Racial and ethnic disparities in Cardio-Oncology: a call to action. JACC CardioOncol. 2021;3(2):201\u20134.","journal-title":"JACC CardioOncol"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-024-05537-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-024-05537-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-024-05537-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T14:03:42Z","timestamp":1722866622000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-024-05537-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,5]]},"references-count":113,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["5537"],"URL":"https:\/\/doi.org\/10.1186\/s12967-024-05537-5","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,5]]},"assertion":[{"value":"7 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no potential competing interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"739"}}